Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and... see more

Recent & Breaking News (NDAQ:VRDN)

Viridian Therapeutics to Participate in June Investor Conferences

GlobeNewswire June 1, 2022

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

GlobeNewswire May 12, 2022

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

GlobeNewswire May 3, 2022

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

GlobeNewswire April 6, 2022

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

GlobeNewswire April 4, 2022

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

GlobeNewswire March 21, 2022

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

GlobeNewswire March 14, 2022

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

GlobeNewswire March 10, 2022

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

GlobeNewswire March 3, 2022

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

GlobeNewswire February 14, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

GlobeNewswire January 31, 2022

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

GlobeNewswire January 4, 2022

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

GlobeNewswire December 20, 2021

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 30, 2021

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

GlobeNewswire November 15, 2021

Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

GlobeNewswire November 4, 2021

Viridian Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 3, 2021

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

GlobeNewswire October 14, 2021

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

GlobeNewswire September 30, 2021

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 23, 2021